GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Avenir Wellness Solutions AVRW · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Avenir Wellness Solutions

Its shares trade under the ticker AVRW. It has been listed since 11 May 2016. In the fiscal year to 31 December 2023, it reported revenue of $4.3m and a net loss of $3.4m. At that date it held total assets of $2.6m and shareholders' equity of −$9.9m.

CURE Pharmaceutical Holding Corp. is a biopharmaceutical company. The company is headquartered in Oxnard, California. The company went IPO on 2016-05-11. The firm is focused on the development and manufacturing of drug formulation and drug delivery technologies. Its technology platform includes oral dissolving film (ODF), and encapsulation systems (microCURE) compatible with ODF, chews, oral solutions, topical and transdermal dose forms. The ODF products are composed of excipients such as polymers, stabilizers, lipids and surfactants. Its technologies deliver active ingredients to the gastrointestinal tract when placed on the tongue and swallowed, or directly to the blood stream when placed under the tongue (sublingual) or on the inner lining of the cheek and lip (buccal). Its pharmaceutical drug program includes CUREfilm Blue and CUREfilm Canna. CUREfilm Blue is a sildenafil ODF for the treatment of erectile dysfunction. CUREfilm Canna is engaged in developing several cannabinoid products with optimized pharmacokinetic profiles using microCURE and CUREfilm technology.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
11 May 2016
Employees
19

Leadership

Pay as last reported

  • Mr. Robert DavidsonNon-Executive Chairman of the Board, since 2011$62,119
  • Ms. Nancy DuitchChief Executive Officer, Director$275,000
  • Mr. Joel BennettChief Financial Officer and Accounting Officer, Treasurer, Secretary$220,000
  • Mr. Gerald BaggIndependent Director$45,119
  • Mr. Robert CostantinoIndependent Director$55,038
  • Dr. Gene SalkindIndependent Director$42,500
  • Mr. Dov SzapiroIndependent Director$45,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cure Pharmaceutical Holding Corp has several strengths that contribute to its success and competitive advantage:

Weaknesses

  • Despite its strengths, Cure Pharmaceutical Holding Corp also faces certain weaknesses that may hinder its growth and competitiveness:

Opportunities

  • Cure Pharmaceutical Holding Corp can leverage several opportunities in the market to further its growth and success:

Threats

  • Cure Pharmaceutical Holding Corp must be aware of the following threats that could impact its business negatively:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.